Compare Novo Nordisk A/S (NVO) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| NVO | SGOV | |
|---|---|---|
Market Cap | $165.31B | $114.40B |
Volume | 11,432,838 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $100.72 |
52-Week Low | $35.29 | $100.28 |
Typical Hold Time | 116 Days | 50 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.47 with minimal daily movement, reflecting its ultra-short-term Treasury focus. The technical picture shows bearish momentum with moving averages signaling caution, though oversold RSI levels suggest potential stabilization. Recent institutional activity includes Envestnet Asset Management reducing its position by 13.2% in Q2 2026 (SEC filing, September 25, 2026).
As a Treasury ETF, SGOV offers low volatility and regular dividend distributions, with recent payouts around $0.30-$0.31. However, rising bond yields and Federal Reserve policy uncertainty create headwinds. The fund provides capital preservation but limited growth potential in a rising rate environment, making it suitable for defensive positioning rather than aggressive growth strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
